Research from Baylor Scott & White featured in updated gastroesophageal reflux disease clinical guidelines

Gastroesophageal reflux disease (GERD) is estimated to affect nearly 20% of Americans. Recent advances in our understanding of GERD have changed clinical practice. Therefore, in February 2022, the American College of Gastroenterology (ACG) released an updated set of guidelines for the diagnosis and management of GERD. Research from Baylor University Medical Center (Baylor Dallas), part of Baylor Scott & White Health, helped shape these new practice guidelines.

Read more

Translational research fuels discovery at Baylor Scott & White Research Institute

Baylor Scott & White Research Institute (BSWRI) is well known for its diverse research portfolio. The program actively maintains nearly 2,000 active and enrolling projects across more than 50 medical specialties each year, including initiatives supported by its translational research program. The program is focused on driving innovation by working with clinical teams across the Baylor Scott & White Health System to develop new medicines and diagnostic tests. The translational research team’s approach to discovery of “bench-to-bedside- and- back-to-bench” allows BSWRI to continue to be a major contributor to advancements in medical science.

Read more

Preemptive kidney transplant improves outcomes for patients with chronic kidney disease

For patients with advanced chronic kidney disease, getting a preemptive kidney transplant may lead to a longer and healthier life. A preemptive kidney transplant is when a patient receives a new kidney before he or she needs to go on dialysis.

Read more

Baylor Scott & White launches effort to improve inpatient care of patients with cirrhosis

Patients who are admitted to the hospital with cirrhosis have significant morbidity and mortality when they present with complications of end-stage liver disease. Complications such as hepatic encephalopathy and gastrointestinal bleeding lead to increased length of stay, readmission, intensive care utilization and inpatient mortality.

Read more

Meet the newest members of the Baylor Dallas lung care team

Michael Duncan, MD, is chief of pulmonary, critical care and sleep medicine at Baylor University Medical Center at Dallas, part of Baylor Scott & White Health. His expertise includes lung transplantation, pulmonary hypertension and extracorporeal membrane oxygenation (ECMO). Dr. Duncan also has experience in cardiovascular critical care.

Read more

Baylor Scott & White expands advanced lung disease outreach program

Caring for patients with advanced lung disease requires significant infrastructure and special physician expertise. To assist general pulmonologists in smaller Texas communities, Baylor University Medical Center at Dallas (Baylor Dallas), part of Baylor Scott & White Health, has established outreach clinics in Abilene, Amarillo, Lubbock and Tyler.

Read more

Recent updates modify definition of pulmonary hypertension

The understanding of pulmonary hypertension (PH) continues to slowly evolve over time. At the 6th World Symposium on Pulmonary Hypertension in 2018, the threshold to diagnose PH was lowered to mPAP ≥ 20 mmHg. Most recently, the 2022 guidelines issued by the European Society of Cardiology and European Respiratory Society added to this new definition by lowering the threshold for pulmonary vascular resistance (PVR) to >2 instead of >3.

“Pulmonary hypertension is a rare disease that is inherently progressive in nature. Untreated PH results in progressive right ventricular failure, and, ultimately, death,” says Chetan Naik, MD, MS, medical director of the pulmonary hypertension program and transplant pulmonologist on the medical staff at Baylor University Medical Center at Dallas (Baylor Dallas), part of Baylor Scott & White Health. “This latest change to the PVR number is another step in increasing our ability to diagnose PH early so that patients may be regularly screened or started on effective therapy before the disease progresses.”

Patients who should be screened early and regularly include those at risk for PH due to familial disease or those who have co-morbid conditions that predispose them to PH. PH should also always be in the differential diagnosis of unexplained dyspnea. Because echocardiography remains an important screening tool – it is noninvasive and easily accessible – Baylor Dallas has instituted a new PH-specific limited protocol echocardiogram to identify additional signs of PH in at-risk patients.

“I can’t emphasize enough how important early detection of PH is,” says Dr. Naik. “While vasodilators are the backbone of therapy for PH, we have at least 10 medications that are efficacious against the disease. All are designed to lower blood pressure within the lungs and help the right ventricle recover. In addition, Baylor Dallas is the site of several clinical trials of next-generation PH medications that target the underlying pathophysiological mechanisms of the disease, and many of our patients are candidates for these trials.

Because PH can develop as a primary disease of the pulmonary arteries or can complicate diseases affecting the heart, lungs and certain systemic disorders, management of the disease requires a multidisciplinary approach. The Baylor Dallas pulmonary hypertension program is designed to facilitate collaboration among advanced lung disease specialists, advanced heart failure specialists, transplant pulmonologists and thoracic surgeons. These physicians work closely with allied services, including genetic counselors, physiotherapists, dieticians & palliative care services.

The Baylor Dallas pulmonary hypertension program was established more than 12 years ago and follows more than 600 patients in outpatient clinics at Baylor Dallas and Baylor Scott & White All Saints Medical Center – Fort Worth. While lung transplant is rarely indicated for PH as a result of medication efficacy, Baylor Dallas has a robust program lung transplantation for patients with advanced PH who are refractory to medical therapy.

To learn more about the Center for Advanced Lung Disease at Baylor Dallas, call 214.820.6856.

Related articles